Chondroitin sulfate proteoglycans: Key modulators in the developing and pathologic central nervous system

• Published in: Experimental neurology 2015-07, Vol.269, p.169-187
• Main Authors: Dyck, Scott M., Karimi-Abdolrezaee, Soheila
• Format: Article
• Language: English
• Subjects: Animals; Axonal regeneration; Brain Injuries - drug therapy; Central; Central Nervous System - drug effects; Central Nervous System - metabolism; Chondroitin sulfate proteoglycans; Chondroitin Sulfate Proteoglycans - metabolism; Chondroitin Sulfate Proteoglycans - pharmacology; Development; Extracellular matrix; Glial scar; Humans; Intacellular mechanisms; LAR; Multiple sclerosis; Nerve Regeneration - drug effects; Nerve Regeneration - physiology; Nervous system; Neuronal Plasticity - drug effects; Plasticity; PTPσ; Spinal Cord Injuries - drug therapy; Spinal cord injury
• ISSN: 0014-4886; 1090-2430
• DOI: 10.1016/j.expneurol.2015.04.006

Chondroitin Sulfate Proteoglycans (CSPGs) are a major component of the extracellular matrix in the central nervous system (CNS) and play critical role in the development and pathophysiology of the brain and spinal cord. Developmentally, CSPGs provide guidance cues for growth cones and contribute to the formation of neuronal boundaries in the developing CNS. Their presence in perineuronal nets plays a crucial role in the maturation of synapses and closure of critical periods by limiting synaptic plasticity. Following injury to the CNS, CSPGs are dramatically upregulated by reactive glia which form a glial scar around the lesion site. Increased level of CSPGs is a hallmark of all CNS injuries and has been shown to limit axonal plasticity, regeneration, remyelination, and conduction after injury. Additionally, CSPGs create a non-permissive milieu for cell replacement activities by limiting cell migration, survival and differentiation. Mounting evidence is currently shedding light on the potential benefits of manipulating CSPGs in combination with other therapeutic strategies to promote spinal cord repair and regeneration. Moreover, the recent discovery of multiple receptors for CSPGs provides new therapeutic targets for targeted interventions in blocking the inhibitory properties of CSPGs following injury. Here, we will provide an in depth discussion on the impact of CSPGs in normal and pathological CNS. We will also review the recent preclinical therapies that have been developed to target CSPGs in the injured CNS. •CSPGs have a critical role in the development, maintenance and pathology of the CNS.•Following injury to the CNS, CSPGs expression is markedly upregulated.•CSPGs limit cell replacement, axonal sprouting, regeneration and remyelination.•Inhibiting CSPGs function is a realistic therapeutic target for repair following SCI.•Recent discovery of four CSPGs receptors provide novel therapeutic targets for SCI.